Literature DB >> 28722778

Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture.

Cristina E Rodríguez1, Damian E Berardi1, Marianela Abrigo1, Laura B Todaro1, Elisa D Bal de Kier Joffé1, Gabriel L Fiszman1.   

Abstract

Breast cancer human cells culture as spheroids develop autophagy and apoptosis, which promotes Trastuzumab resistance in HER2 overexpressing cells. Our aim was to study the association of the hostile environment developed in 3D with the breast cancer stem cells population and the HER2 modulation. Human mammary adenocarcinoma cell lines were cultured as spheroids using the hanging drop method. We generated hypoxia conditions by using a hypoxic chamber and CoCl2 treatment. Breast cancer stem cells were measured with mammosphere assays, the analysis of CD44 + CD24low population by flow cytometry and the pluripotent gene expression by RT-qPCR. HER2 expression was evaluated by flow cytometry and Western blot. MTS assays were conducted to study cell viability. Hostil environment developed in spheroids, defined by hypoxia and autophagy, modulated the response to Trastuzumab. In HER2+ cells with acquired resistance, we observed an increase in the breast cancer stem cell population. In BT474 spheroids, Trastuzumab induced the acquisition of resistance, along with an increase in breast cancer stem cells. Also, in 3D culture conditions we determined a modulation in the HER2 expression. Moreover, breast cancer stem cells showed enhanced HER2 expression. Finally, cells without HER2 gene amplification cultured as spheroids were sensitive to Trastuzumab, diminishing HER2 expression and cancer stem cells. Our findings show that 3D architecture is able to modulate breast cancer stem cell population and HER2 distribution, modifying the cell response to Trastuzumab.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28722778     DOI: 10.1002/jcb.26298

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  13 in total

1.  Three dimensional engineered models to study hypoxia biology in breast cancer.

Authors:  Vaishali Aggarwal; Oshin Miranda; Paul A Johnston; Shilpa Sant
Journal:  Cancer Lett       Date:  2020-06-20       Impact factor: 8.679

2.  Exploring Amodiaquine's Repurposing Potential in Breast Cancer Treatment-Assessment of In-Vitro Efficacy & Mechanism of Action.

Authors:  Vineela Parvathaneni; Rameswari Chilamakuri; Nishant S Kulkarni; Nabeela F Baig; Saurabh Agarwal; Vivek Gupta
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

3.  Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells.

Authors:  Yuqiu Chen; Jiawei Xu; Wang Pan; Xiaofan Xu; Xueping Ma; Ya'nan Chu; Lu Wang; Shuyun Pang; Yujiao Li; Bingjie Zou; Guohua Zhou; Jun Gu
Journal:  Thorac Cancer       Date:  2022-05-22       Impact factor: 3.223

4.  CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer.

Authors:  Yuyi Wang; Li Tu; Chi Du; Xiaoxiao Xie; Yanyang Liu; Jiantao Wang; Zhixi Li; Ming Jiang; Dan Cao; Xi Yan; Feng Luo
Journal:  Onco Targets Ther       Date:  2018-09-06       Impact factor: 4.147

Review 5.  Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance.

Authors:  Sangita Sridharan; Cory M Howard; Augustus M C Tilley; Boopathi Subramaniyan; Amit K Tiwari; Randall J Ruch; Dayanidhi Raman
Journal:  Front Oncol       Date:  2019-10-16       Impact factor: 6.244

6.  Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model.

Authors:  Zhaoming Huang; Panpan Yu; Jianhui Tang
Journal:  Onco Targets Ther       Date:  2020-06-11       Impact factor: 4.147

7.  Atorvastatin-mediated rescue of cancer-related cognitive changes in combined anticancer therapies.

Authors:  Junho Lee; Jin Su Kim; Yangjin Kim
Journal:  PLoS Comput Biol       Date:  2021-10-20       Impact factor: 4.475

Review 8.  Dual or multiple drug loaded nanoparticles to target breast cancer stem cells.

Authors:  Yu Gao; Mingtan Tang; Euphemia Leung; Darren Svirskis; Andrew Shelling; Zimei Wu
Journal:  RSC Adv       Date:  2020-05-19       Impact factor: 4.036

9.  3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity.

Authors:  Sneha Gopal; Seok-Joon Kwon; Bosung Ku; Dong Woo Lee; Jungeun Kim; Jonathan S Dordick
Journal:  Commun Biol       Date:  2021-07-21

10.  Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a Tissue Engineered Breast Cancer Model.

Authors:  Kayla F Goliwas; Jillian R Richter; Hawley C Pruitt; Lita M Araysi; Nicholas R Anderson; Rajeev S Samant; Susan M Lobo-Ruppert; Joel L Berry; Andra R Frost
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.